METHAZOLAMIDE · BAUSCH AND LOMB INC
Methazolamide Tablets are indicated in the treatment of ocular conditions where lowering intraocular pressure is likely to be of therapeutic benefit, such as chronic open-angle glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where lowering the intraocular pressure is desired before surgery.
Details
- Status
- Prescription
- First Approved
- 1959-01-26
- Routes
- ORAL
- Dosage Forms
- TABLET
Companies
METHAZOLAMIDE Approval History
What METHAZOLAMIDE Treats
1 indicationsMETHAZOLAMIDE is approved for 1 conditions since its original approval in 1993. These indications span multiple therapeutic areas including oncology, immunology, and more.
METHAZOLAMIDE Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to METHAZOLAMIDE
3 of 16FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
BAUSCH AND LOMB INC's other novel FDA approvals
Other CDER-designated drugs from the same sponsor (2016–2025).
Clinical Trial Registry
7 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT02390284 STOP-RGCD results posted | 20140587 R01EY014957 | Ph 3 | terminated | Stop Retinal Ganglion Cell Dysfunction Study |
| NCT06312800 | LeWitt02 | Ph 2 | withdrawn | Acamprosate and Methazolamide for Essential Tremor |
| NCT02463357 results posted | 15-0254 | Ph 4 | completed | Three New Ideas to Protect Special Forces From the Stress of High Altitude |
| NCT02758470 | H16-00896 | Ph 4 | completed | Muscle Fatigue and Carbonic Anhydrase Inhibitors |
| NCT01587027 results posted | GQ01 DARPA | Ph 1 | completed | Safety Evaluation of Aminophylline and Methazolamide |
| NCT02760121 | H16-00028 | Ph 4 | completed | AZ, MZ, and the Pulmonary System Response to Hypoxia |
| NCT01702025 results posted | N66001-10-C-2134 | Ph 1, Ph 2 | completed | Rapid Acclimatization to Hypoxia at Altitude |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
METHAZOLAMIDE FDA Label Details
Indications & Usage
Methazolamide Tablets are indicated in the treatment of ocular conditions where lowering intraocular pressure is likely to be of therapeutic benefit, such as chronic open-angle glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where lowering the intraocular pressure is desired before surgery.
Looking for the branded version?
NEPTAZANE
Full clinical data, patents, trials, and competitive landscape for methazolamide.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.